Medsolve Dynamics

Medsolve Dynamics

Short, operator-level strategy for radiation oncology and cancer program leaders navigating margin pressure, capital decisions, and AI reality. No fluff. No pitch. Just what the vendor isn't telling you.

  1. 26 июн.

    Why a One-Hour LINAC downtime Becomes a Three-Hour Day in Radiation Oncology

    Parts lead time and field-engineer coverage, not the uptime percentage in your contract, decide how long a LINAC is actually down. A vendor-side look at how service coverage models are built around the vendor's cost, not your schedule, and what that costs your throughput and margin. LINAC downtime, service coverage, parts logistics, field engineer, uptime SLA, throughput, time toxicity. medsolvedynamics.com team@medsolvedynamics.com

    2 мин.

  2. 26 июн.

    The Tell in a LINAC Service Contract: Same Rate on a New Machine and a Twenty-Year-Old One

    A radiation oncology service contract that quotes the same rate on a one-year-old LINAC and a twenty-year-old one was never priced on the cost to serve the machine. It was priced to anchor you. How to make a LINAC service price prove it is tied to cost. LINAC service contract, service pricing, capital negotiation, vendor negotiation, AMAC, purchasing framework. medsolvedynamics.com team@medsolvedynamics.com

    2 мин.

  3. 19 июн.

    What Every New Radiation Oncology Administrator Should Know Before Their First Vendor Meeting

    Your first capital negotiation is against someone who runs forty a year. This explains where the vendor puts the leverage and how a new administrator levels the field. New administrator, capital negotiation, vendor meeting, supervision coverage, radiation oncology.

    2 мин.

  4. 17 июн.

    Why a Discount Off List Is Not a Number You Can Trust in Radiation Oncology Capital

    A percentage off a list price the vendor set themselves tells you very little. This explains why the value package matters more than the discount in a LINAC capital negotiation, and what a program should structure for instead. Capital strategy, vendor quote, service contract, radiation oncology. medsolvedynamics.com team@medsolvedynamics.com

    1 мин.

  5. 11 июн.

    Why AI Efficiency Disappears Between the Demo and the Staffing Model.

    Vendor AI demos show real efficiency that never reaches the staffing model. The workflow redesign and oversight cost behind AI value in radiation oncology. medsolvedynamics.com | team@medsolvedynamics.com #AIinHealthcare #RadiationOncology #WorkflowFit #OncologyOperations

    1 мин.

  6. 11 июн.

    Why a Radioligand No-Show Costs Differently Than a Missed Fraction.

    Lutetium-177 has a half-life of about 6.6 days, so a radioligand therapy no-show is a paid dose decaying in your department. The dose economics behind theranostics scheduling and isotope supply. medsolvedynamics.com | team@medsolvedynamics.com #Theranostics #RadioligandTherapy #IsotopeSupply #OncologyOperations

    1 мин.

  7. 4 июн.

    Why AI Is Not a One-Time Purchase in Radiation Oncology

    AI purchasing differs fundamentally from traditional capital and software decisions. The cost is not the license, it is the recurring monitoring as the model drifts in ways no tolerance table catches. From hype to value: how to evaluate AI for long-term cost structure, clinical accountability, and organizational readiness, not the demo. medsolvedynamics.com | team@medsolvedynamics.com  #RadiationOncology #AIinHealthcare #OncologyLeadership #HealthcareAI

    2 мин.

  8. 3 июн.

    Why a Theranostics No-Show Hurts Differently Than an IMRT One

    In radiation oncology, a curative no-show is a slot you backfill. In theranostics, the Lu-177 dose is a fixed amount with about a five-day shelf life, scheduled for one patient, and it cannot wait for a better day. Here is how scheduling discipline, authorized user coverage, and capture mechanics determine whether a theranostics service line holds its margin, and the two operating costs the vendor proforma leaves out. medsolvedynamics.com | team@medsolvedynamics.com  #Theranostics #RadiationOncology #RadiopharmaceuticalTherapy #OncologyOperations

    2 мин.
См. все (68)

Оценки и отзывы

5
из 5
Оценок: 2

Об этом подкасте

Short, operator-level strategy for radiation oncology and cancer program leaders navigating margin pressure, capital decisions, and AI reality. No fluff. No pitch. Just what the vendor isn't telling you.

Информация

  • Автор
    Medsolve Dynamics
  • Годы выхода
    2 тыс.
  • Выпуски
    68
  • Ограничения
    Без ненормативной лексики
  • Авторские права
    © 2026 Medsolve Dynamics